Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers (Q46049613)

19 December 2017

title

Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers (English)

1 reference

19 December 2017

author name string

S V Vormfelde

1

1 reference

19 December 2017

J Brockmöller

2

1 reference

19 December 2017

S Bauer

3

1 reference

19 December 2017

P Herchenhein

4

1 reference

19 December 2017

J Kuon

5

1 reference

19 December 2017

I Meineke

6

1 reference

19 December 2017

I Roots

7

1 reference

19 December 2017

J Kirchheiner

8

1 reference

19 December 2017

language of work or name

English

0 references

publication date

15 April 2009

1 reference

19 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

19 December 2017

volume

86

1 reference

19 December 2017

issue

1

1 reference

19 December 2017

page(s)

54-61

1 reference

19 December 2017

Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Clinical consequences of cytochrome P450 2C9 polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Genetic variation at the CYP2C locus and its association with torsemide biotransformation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

CYP2C9 allelic variants: ethnic distribution and functional significance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Quantitative analysis of constitutive and inducible CYPs mRNA expression in the HepG2 cell line using reverse transcription-competitive PCR.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

The mechanism of the warfarin-rifampin drug interaction in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Pharmacokinetic interactions with rifampicin : clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

In Vivo Induction of Liver P-Glycoprotein Expression by Xenobiotics in Monkeys

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Nuclear receptor coactivator 6 mediates the synergistic activation of human cytochrome P-450 2C9 by the constitutive androstane receptor and hepatic nuclear factor-4alpha

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Effect of rifampicin on the pharmacokinetics of pioglitazone

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Pharmacogenetics-based therapeutic recommendations — ready for clinical practice?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Pharmacogenetics: From Bench to Byte

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Differential genotype dependent inhibition of CYP2C9 in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.40

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.40

1 reference

19 December 2017

Dimensions Publication ID

1007578042

0 references

1 reference

19 December 2017